NEW DELHI: Pfizer ha said that an early peek at the data of vaccine suggests that it might be 90 per cent effective at preventing the COVID-19 infection. This revelation has showed that the company is on the right track to file an emergency use application with United States of America (USA) regulators.
The analysis is provided by an independent data monitoring board which looked at 94 infections recorded so far in the study. Pfizer Inc. has not disclosed any more information regarding the cases and said that initial protection rate may change by the end of the study.
The vaccine made by Pfizer and its German partner BioNTech are among the vaccines which are at late-stage trails around the world. The volunteers and researchers don’t know who received the real vaccine or a dummy shot. After one week of the second dose, they began counting the number of infections but the number is not clear as the study is still under process. However, doing the math it is evident that the counted infections are all from the people who got dummy shot.